{
  "id": 17258819,
  "title": "Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO",
  "url": "https://urgent.news/2026/10/30/gilead-backed-aspen-neuroscience-shares-decline-2-after-us-ipo",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T15:53:45.000Z",
  "source": {
    "name": "Bloomberg",
    "slug": "bloomberg",
    "url": "https://www.bloomberg.com/news/articles/2026-10-30/gilead-backed-aspen-neuroscience-shares-decline-2-after-us-ipo"
  },
  "original_language": "en",
  "account": null,
  "summary": "Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}